-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...
More »SEARCH RESULT
A just order
-The Hindu The Supreme Court order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...
More »Artful claims can’t decide patent law: court-J Venkatesan
-The Hindu The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug. A Bench of Justices Aftab Alam and Ranjana Desai said, "We certainly do not wish the law of patent... to develop on the lines where there may be a vast...
More »We will not yield to pressure to grant patents, says Sharma-Sujay Mehdudia
-The Hindu Union Commerce and Industry Minister Anand Sharma has termed "historic" the Supreme Court's rejection of Novartis' claim for patent for its anti-cancer drug Glivec. He said the Indian Patent Act was in conformity with its international obligations under the Trade Related Aspects of Intellectual Property Rights Agreement. "It is a historic judgment. It reaffirms the position of Indian law and, in particular, provisions of Section 3D, which mandates... a substantive...
More »Justice Big Mouth- Rahul Kotiyal and Ajachi Chakrabarti
-Tehelka A public issue is not truly public unless Markandey Katju has passed judgement. Rahul Kotiyal and Ajachi Chakrabarti stand downwind "Journalists" writes Markandey Katju, with little sense of irony, "comment on everything under the sun." He goes on to say that when the shoe is on the other foot, when someone comments on journalism, it is misconstrued as an attack on press freedom. That when he announces he is appointing a...
More »